{
    "nctId": "NCT01730729",
    "briefTitle": "Cabergoline in Metastatic Breast Cancer",
    "officialTitle": "A Pilot Phase II Trial of Cabergoline in the Treatment of Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Recurrent Breast Cancer, Stage IV Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "EARLY_PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Overall Response Rate (ORR) at 2 Months",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must have histologically confirmed metastatic breast cancer; tissue (a minimum of 3 slides) from the most recent biopsy is required for review and confirmation of eligibility; NOTE: material should ideally be from the metastatic disease, however material from the primary tumor is acceptable if that is all that is available\n* Patients must have stage IV breast cancer\n* Patients must have tumors (primary or metastatic) that stain positively for the prolactin receptor\n* Patients may have measurable or evaluable disease\n\n  * Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\> 20 mm with conventional techniques or as \\> 10 mm with spiral CT scan\n  * Evaluable disease is disease that does not meet the criteria for measurable disease; examples would include patients with effusions or bone-only disease\n* Women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study\n* Patients must have a life expectancy of greater than 12 weeks\n* Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =\\< 2\n* Patients may have had a prior diagnosis of cancer if it has been \\> 5 years since their last treatment\n* Leukocytes \\>= 3,000/uL (microliter)\n* Absolute neutrophil count \\>= 1,500/uL\n* Platelets \\>= 100,000/uL\n* Child Pugh score =\\< 10\n* Patients must be able to swallow and retain oral medication\n* All patients must have given signed, informed consent prior to registration on study\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating are not eligible for study treatment\n* Patients who are undergoing concomitant radiotherapy are NOT eligible for participation\n* Patients who are receiving any other investigational agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment is allowed with a 2 week washout period prior to registration\n* Patients who are taking any herbal (alternative) medicines are NOT eligible for participation; patients must be off any such medications by the time of registration\n* Patients who are receiving concomitant D2-antagonists (such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide) are NOT eligible for participation; patients must be off any such medications by the time of registration\n* Patients with known brain metastases are NOT eligible for participation\n* Patients with any of the following conditions or complications are NOT eligible for participation:\n\n  * Uncontrolled hypertension\n  * Known hypersensitivity to ergot derivatives\n  * History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve (to be determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis)\n  * History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders\n  * Gastrointestinal (GI) tract disease resulting in an inability to take oral medication\n  * Malabsorption syndrome\n  * Require intravenous (IV) alimentation\n  * History of prior surgical procedures affecting absorption\n  * Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}